Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:6/1/2009

tabine (GEM) in Patients (pts) with Advanced Cancer." The results, which were previously announced in March 2009, demonstrated that the combination of REOLYSIN and gemcitabine was well tolerated, and resulted in disease control for a majority of the patients. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and/or clinical responses and five patients had SD for 4-8 cycles, for a total disease control rate (CR (Complete Response)+PR+SD) of 70%.

Dr. Sanjay Goel and colleagues delivered a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors." The results, which were previously announced in June 2007, demonstrated that REOLYSIN was well tolerated. Of 18 patients treated in the trial, eight demonstrated SD or better as measured by Response Evaluation Criteria in Solid Tumors (RECIST) including a patient with progressive breast cancer who experienced a PR (34% shrinkage in tumor volume).

All three posters will be available today on the Oncolytics website at www.oncolyticsbiotech.com

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
2. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
3. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
6. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
7. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
8. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
10. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Audacity, a ... agency and member of the Huntsworth Health Group, is ... its executive team. In her role, Gonzales will serve ... “We are incredibly honored to welcome a talent of ... and CEO, Gaëtan Fraikin. “She is a proven healthcare ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... Agritech Limited (NASDAQ GS: SEED) (" Origin ", or the ... China , today announced that the Company ... 30, 2014, before the market opens on Thursday, January 8, ... January 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... To participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... The DNA Microarray market market was ... expected to grow at a CAGR of 15.2% ... TOC of the DNA Microarray for an in-depth ... help of various tables and figures. , ... consists of instrument, consumables, and services, where the ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... fusions in lysates of the yeast Saccharomyces cerevisiae using the , ... , Paul Gavin # and Mark Prescott # ... # Department of Biochemistry and Molecular ... Australia , * Technical assistance: Varian Australia Pty ...
... Overview , Affinity ... number of biological molecules. For example, antibodies may be purified based ... purified on the basis of its affinity for a monospecific antibody ... column with a relatively large volume. This note discusses the use ...
... Purpose , ... be identified and quantified more effectively and efficiently using LC/MS/MS. These ... challenges. , Overview ... safety organizations worldwide are placing great importance on the identification and ...
Cached Biology Technology: Monitoring fluorescence resonance energy transfer (FRET) between GFP, fusions in lysates of the yeast Saccharomyces cerevisiae using the , Varian, Cary Eclipse 2 Monitoring fluorescence resonance energy transfer (FRET) between GFP, fusions in lysates of the yeast Saccharomyces cerevisiae using the , Varian, Cary Eclipse 3 Monitoring fluorescence resonance energy transfer (FRET) between GFP, fusions in lysates of the yeast Saccharomyces cerevisiae using the , Varian, Cary Eclipse 4Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 2Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 3Identification of Insecticides and Herbicides by LC/MS/MS Using the API 2000 LC/MS/MS System 2
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug Association ... regulatory agencies will speak and at least seven more will ... at the Omni Shoreham Hotel in Washington D.C. ... again to have significant support from the regulatory agencies in ... Europe in our effort to help advance the ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... of Rochester Medical Center scientists have demonstrated a new ... sometimes dangerous E. coli bacteria. , The unique technology ... of the sensing system that also includes a silicon ... and Bioelectronics published an article on the technology in ...
... clinical trial demonstrate that high doses of an experimental ... healthy adults. , Approximately half of those volunteers ... the highest dosage of the vaccine tested in the ... predict would neutralize the virus. The National Institute of ...
... estate may be its most important feature to many ... San Diego (UCSD) and the University of Virginia have ... distributed along the chromosomes of bacteria and simpler organisms ... , In a paper published Jan. 13 online in ...
Cached Biology News:Rochester scientists develop fast-working biosensor 2H5N1 avian flu virus vaccine induces immune responses in healthy adults 2H5N1 avian flu virus vaccine induces immune responses in healthy adults 3Patterns in genome organization may partially explain how microbial cells work 2Patterns in genome organization may partially explain how microbial cells work 3
... and Freedom EVO384R are fast multi-channel pipetting ... three different sizes, with a multi-channel head ... significant time saving, with true parallel processing ... of your assays with the Freedom EVOware ...
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
Biology Products: